Reviva Pharmaceuticals Bolsa (NASDAQ: RVPH)

Últimas noticias sobre Reviva Pharmaceuticals (NASDAQ:RVPH) Bolsa

Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals Holdings Inc

Reviva Pharmaceuticals Holdings, Inc. - Warrants

RBC Capital analyst James McGarragle maintains CAE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CAE#TSX">CAE</a>) with a Outperform and raises the price target from C$27 to C$34.

News

Price Target

Analyst Ratings

TSX:CAE

RBC Capital Maintains Outperform on CAE, Raises Price Target to C$34

Scotiabank analyst Phil Hardie maintains Element Fleet Mgmt (TSX:<a class="ticker" href="https://www.benzinga.com/stock/EFN#TSX">EFN</a>) with a Sector Outperform and lowers the price target from C$33 to C$32.

TSX:EFN

Scotiabank Maintains Sector Outperform on Element Fleet Mgmt, Lowers Price Target to C$32

RBC Capital analyst Pammi Bir maintains Crombie REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CRR#TSX">CRR</a>) with a Sector Perform and raises the price target from C$15 to C$16.

TSX:CRR

TSX:CRR/UN

RBC Capital Maintains Sector Perform on Crombie REIT, Raises Price Target to C$16

Scotiabank analyst Divya Goyal maintains Converge Tech Solns (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CTS#TSX">CTS</a>) with a Sector Perform and lowers the price target from C$5 to C$4.

TSX:CTS

Scotiabank Maintains Sector Perform on Converge Tech Solns, Lowers Price Target to C$4

Hims &amp; Hers Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares are trading lower in possible response to Amazon.com Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) new upfront pricing for <a href="https://www.benzinga.com/topic/telehealth">telehealth visits and treatment plans</a>. 
What Happened: Amazon announced Thursday that its Amazon One Medical telehealth service is introducing low upfront pricing for clinical visits and treatment plan, as well as free medication delivery for Prime members.
Prime members can now see the total monthly cost or individual use cost for Amazon One Medical Pay-per-visit virtual visits and medications from the Amazon Pharmacy before signing up for care.
"This simple care experience was built to meet the needs of today's customer. At Amazon, we're working to reduce the burden on patients who'd like to move forward with care, but may be tired of navigating the hurdles of our health care system, waiting in a long line at the pharmacy, or worried about a surprise bill or medication cost," said Vin Gupta, chief medical officer for Amazon Pharmacy. 
Prime members who use Amazon Pharmacy will pay a low, upfront price for medications and get those medications delivered for free for a range of common health, beauty and lifestyle concerns including anti-aging skin care treatment, men&#8217;s hair loss, erectile dysfunction and motion sickness.
See Also: <a href="https://www.benzinga.com/general/biotech/24/11/41964382/amazons-secret-fertility-tracker-project-launched-under-jeff-bezos-reportedly-halted-amid-ceo-andy-jassys-cost-cutting-drive">Amazon&#8217;s Secret Fertility Tracker Project Launched Under Jeff Bezos Reportedly Halted Amid CEO Andy Jassy&#8217;s Cost-Cutting Drive</a>
Hims &amp; Hers Health shares moved lower on the news. The company&#8217;s strategy involves bringing customers convenient, transparent and affordable access to care. 
In the third quarter, Hims &amp; Hers subscribers jumped 44% year-over-year to 2 million. The company&#8217;s revenue was up 77% year-over-year to $401.6 million, and Hims &amp; Hers raised its full-year outlook to $1.46 billion to $1.465 billion.
&#8220;Our model is rapidly gaining scale, driving accelerating top line growth, improving profitability and strong cash flow. We are seeing this strength across our business,&#8221; CFO Yemi Okupe said in the earnings release.
HIMS Price Action: <a href="http://benzinga.com/quote/HIMS">Hims &amp; Hers Health shares</a> were down 13.8% at $23.77 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Pixabay.

Movers

AMZN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health Stock Is Tumbling Thursday: What's Going On?

International Flavors &amp; Fragrances, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) shares are trading lower on Thursday. The company launched TEXSTAR, which is an enzymatic solution that enhances the texture of dairy and plant-based fermented products by building<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41964577/iff-launches-texstar-pioneering-enzyme-set-to-transform-fresh-fermented-food-textures" rel="noreferrer noopener"> viscosity without added stabilizers</a>.
TEXSTAR allows manufacturers to achieve distinctive textures with simple, consumer-friendly ingredients, while improving supply chain resilience and reducing Scope 3 emissions associated with texturants.
Marianne Toftdal, global product line manager, Dairy Enzymes, IFF, said, &#8220;With nearly two-thirds of U.K. consumers scrutinizing yogurt ingredients as closely as other foods, TEXSTAR&nbsp;allows the creation of delicious, fresh fermented products with creamy, velvety textures that consumers love, using familiar and consumer-accepted ingredients.&#8221;&nbsp;
This month, International Flavors reported a third-quarter adjusted EPS of $1.04, missing the $1.08 estimate, while sales reached $2.92 billion, surpassing <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41758164/iff-reports-third-quarter-2024-results" rel="noreferrer noopener">the $2.83 billion expectation</a>.
Investors can gain exposure to the stock via&nbsp;iShares Emergent Food and AgTech Multisector ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVEG#NASDAQ">IVEG</a>) and Investment Managers Series Trust III FPA Global Equity ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FPAG#BATS">FPAG</a>).
Price Action: IFF shares are down 1.71% at $88.31 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41852733/fragrance-maker-iff-positioned-for-growth-with-revitalized-rd-and-attractive-valuation-analyst" target="_blank" rel="noreferrer noopener">Fragrance Maker IFF Positioned For Growth With Revitalized R&amp;D And Attractive Valuation: Analyst</a></li>
</ul>

Equities

Northern Lights Fund Trust III FPA Global Equity ETF

FPAG

IVEG

IFF's New TEXSTAR Solution Enhances Texture, Cuts Emissions In Dairy & Plant-Based Foods

Wells Fargo &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) shares are up 13% to $73 since the beginning of November. The stock has seen marked strength following Donald Trump's <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">presidential election win</a>, as investors anticipate that his administration's economic policies could create a favorable climate for major banks. 
Trump&#8217;s tax agenda, which includes potential expansions to the 2017 Tax Cuts and Jobs Act, could lower corporate tax rates further, directly boosting Wells Fargo's earnings. 
Given Wells Fargo's large domestic footprint, the bank stands to benefit substantially from reduced tax burdens, which would improve net income and possibly free up additional funds for shareholder returns through dividends or buybacks.
Read Also: <a href="https://www.benzinga.com/24/11/41971559/disneys-q4-boosted-by-streaming-gains-strong-box-office-and-solid-parks-performance">Disney Q4 Earnings: Revenue And Profit Beat, Best Film Studio Performance, 3-Year Outlook And More</a>
What To Know: Trump's stance on regulatory reform is another factor likely driving optimism for Wells Fargo. Under his previous administration, Trump aimed to ease financial industry regulations, including parts of the Dodd-Frank Act, which could lead to a similar approach this time. This deregulation could be advantageous for Wells Fargo as it looks to recover from recent operational and compliance challenges. 
Eased oversight and reduced compliance costs would allow Wells Fargo to focus on core banking activities like consumer lending, small business support and expanding its mortgage portfolio, without the same intensity of regulatory constraints that have limited its growth in recent years.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41971830/producer-inflation-rises-more-than-expected-in-october-should-traders-rethink-interest-rate-cut-path">Producer Inflation Rises More Than Expected In October: Should Traders Rethink Interest Rate Cut Path?</a>
What Else: In addition, Trump's economic policies may create inflationary pressures, especially with proposed spending increases and high tariffs on imported goods. This could prompt the Federal Reserve to keep interest rates elevated, an outcome that would positively impact Wells Fargo's profitability. 
As a bank with a large base of consumer and business loans, Wells Fargo benefits from higher net interest margins when rates are elevated, as it can charge more for lending while controlling deposit costs.
Overall, the combination of potential tax savings, regulatory relief and a higher-rate environment under Trump's policies creates an optimistic outlook for Wells Fargo.
Read Also: <a href="https://www.benzinga.com/news/buybacks/24/11/41971497/tapestry-and-capri-call-off-8-5b-deal-amid-legal-hurdles">Tapestry And Capri Call Off $8.5B Deal Amid Legal Hurdles</a>
<h2 class="wp-block-heading">How To Buy WFC Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Wells Fargo&#8217;s case, it is in the Financials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

What's Going On With Wells Fargo (WFC) Shares

Scotiabank analyst Konark Gupta maintains CAE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CAE#TSX">CAE</a>) with a Sector Perform and raises the price target from C$30 to C$32.5.

Scotiabank Maintains Sector Perform on CAE, Raises Price Target to C$32.5

Hedge Funds

General

WYNN

Amended 13G Shows Tilman Fertitta Increased Stake In Wynn Resorts From 6.22% To 9.9%

RBC Capital analyst James McGarragle maintains Exchange Income (TSX:<a class="ticker" href="https://www.benzinga.com/stock/EIF#TSX">EIF</a>) with a Outperform and raises the price target from C$65 to C$71.

TSX:EIF

RBC Capital Maintains Outperform on Exchange Income, Raises Price Target to C$71

Intuitive Machines Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) shares are volatile Thursday on the heels of the company&#8217;s third-quarter financial results. Here&#8217;s a <a href="https://www.benzinga.com/pressreleases/24/11/g41968968/intuitive-machines-reports-third-quarter-2024-results">rundown of the report</a>.
What To Know: Intuitive Machines reported third-quarter revenue of $58.48 million, beating analyst estimates of $50.89 million, according to<a href="http://pro.benzinga.com"> Benzinga Pro</a>. Total revenue was up 359% on a year-over-year basis.
The company reported a net loss of $80.44 million, versus net income of $14.31 million in the prior year&#8217;s quarter. Backlog grew to $316.2 million in the quarter, the highest in company history. Intuitive Machines ended the quarter with $89.6 million in cash.
&#8220;Intuitive Machines had a very strong&nbsp;third quarter&nbsp;highlighted by key wins, revenue growth, and the largest cash balance in Company history,&#8221; said Steve Altemus, CEO of Intuitive Machines.
&#8220;We made progress across all three pillars by first securing another south pole lunar delivery mission, then winning the Near Space Network Services contract, and finally, continuing to mature both our LTV design in conjunction with our heavy cargo class lander. These strategic revenue streams bring our business thesis clearly into view, allowing us to focus on capturing more operational services, which we believe will provide long-tail revenues with higher margins.&#8221;
Intuitive Machines' moon lander Odysseus made history in February when it touched down on the surface of the moon, making Intuitive Machines the first private company to land on the moon and bringing the U.S. back to the moon for the first time since 1972.
Intuitive Machines said it completed a vehicle propulsion system hot fire for its second lunar mission during the third quarter. The company said it&#8217;s targeting the launch of its second lunar mission in the first quarter.
See Also: <a href="https://www.benzinga.com/general/space/24/11/41961309/rocket-lab-ceo-touts-spacex-rival-status-trump-impact-on-space-as-stock-surges-almost-30">Rocket Lab CEO Touts SpaceX Rival Status, Trump Impact On Space As Stock Surges Almost 30%</a>
Outlook: Intuitive Machines narrowed its full-year revenue outlook to a range of $215 million to $235 million. The company also said it expects continued backlog expansion driven by potential upcoming awards including Near Space Network 1.2 / 1.3 Direct to Earth and LTVS Phase 2, as well as task orders for OMES and Near Space Network 2.2.
Management is currently discussing the quarter on a conference call with investors that kicked off at 8:30 a.m. ET.
LUNR Price Action: <a href="http://benzinga.com/quote/lunr">Intuitive Machines shares</a> were down 7.36% at $10.90 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of Intuitive Machines.

Earnings

SPACE

LUNR

Intuitive Machines Stock Volatile On Q3 Earnings: What You Need To Know

Scotiabank analyst Mario Saric maintains Artis REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AX#TSX">AX</a>) with a Sector Perform and raises the price target from C$7 to C$7.5.

TSX:AX

TSX:AX/UN

Scotiabank Maintains Sector Perform on Artis REIT, Raises Price Target to C$7.5

AC Immune SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIU#NASDAQ">ACIU</a>) revealed data from a Phase 2 clinical trial of its wholly owned anti-alpha-synuclein (a-syn) active immunotherapy candidate for <a href="https://www.benzinga.com/pressreleases/24/11/g41967487/ac-immune-reports-positive-interim-results-from-phase-2-trial-of-aci-7104-056-active-immunotherapy" target="_blank" rel="noreferrer noopener">early Parkinson&#8217;s disease</a>.
Dr. Andrea Pfeifer, CEO of AC Immune, commented: &#8220;The level of immunogenicity after only 3 months of treatment as well as the continued positive safety profile, reinforces the best-in-class characteristics of our clinically validated anti-a-syn active immunotherapy for the treatment of Parkinson&#8217;s disease. We look forward to sharing further updates in H1 2025 including the decision to expand into Part 2 of the VacSYn study.&#8221;
VacSYn is an adaptive, placebo-controlled, and biomarker-based Phase 2 study in patients with early PD, consisting of two parts.
Part 1 includes initial analyses from over 30 patients randomized to receive ACI-7104.56 or placebo.
To date, no clinically relevant safety issues have been reported other than transient injection site reactions (49%) and headaches (18%).
Interim results show positive antibody responses were effectively induced against the target antigen at week 6 after two immunizations and were strongly boostable.
Treatment with the candidate, ACI-7104.056, induced an increase in anti-a-syn antibodies on average 16-fold higher than the placebo background level after three immunizations.
Based on further interim results, including pharmacodynamic data, to be reported in H1 2025, AC Immune may decide to initiate Part 2 of VacSYn with up to 150 patients.
Patients from Part 2 will also be evaluated for the progression of motor and non-motor symptoms of the disease, as well as digital, imaging, and fluid biomarkers.
In May, Takeda&nbsp;Pharmaceutical Company Limited&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>)&nbsp;and&nbsp;AC Immune announced an exclusive, worldwide option and license agreement for AC Immune's active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38797408/why-is-small-cap-alzheimers-focused-ac-immune-stock-trading-higher-on-monday" rel="noreferrer noopener">for Alzheimer's disease</a>.
Price Action: AC Immune stock is up 6.71% at $3.34 during the premarket session at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/41951274/nutanix-catalysts-include-hci-growth-vmware-market-share-shift-and-ai-demand-analyst" target="_blank" rel="noreferrer noopener">Nutanix Catalysts Include HCI Growth, VMware Market Share Shift, And AI Demand: Analyst</a></li>
</ul>

Biotech

Health Care

Trading Ideas

ACIU

AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients

Macro Economic Events

Econ #s

Economics

Natural Gas Storage Build Of 42B Vs 34B Est.; 69B Prior

The S&amp;P 500 Index has traded higher and posted new all-time highs since the 2024 presidential election was<a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election"> won by Donald Trump.</a>
Benzinga readers expect the momentum to continue, with the index nearing impressive election year milestones.
What Happened: The 2024 presidential election win by Donald Trump has created market optimism <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41784504/trumps-win-sends-indices-to-record-highs-financials-small-caps-surge-bitcoin-tops-75-000-w">across the stock market </a>and cryptocurrency sector.
While analysts and experts look for individual stocks and sectors that could benefit under four years with Trump beginning in January 2025, market indexes have soared to record levels.
The SPDR S&amp;P 500 ETF Trust (ARCA :SPY), which tracks the S&amp;P 500 Index, opened for trading at $570.74 on Election Day and closed at $576.70 the same day, ahead of Americans and people around the world knowing the election outcome.
By early morning on Nov. 6, media outlets had declared Trump the winner of the election, and the SPY opened at $589.20, up 2.2% from the previous day.
A recent poll of Benzinga readers shows that market optimism is expected since the Trump victory was declared.
"Will Trump's victory keep the stock market on a winning streak through 2024?" Benzinga asked.
The results were:
<ul>
<li>Yes: 76%</li>
<li>No: 24%</li>
</ul>
The majority of Benzinga readers expect the stock market momentum to continue after Trump's victory, likely meaning that the S&amp;P 500 will continue to gain through the end of the year.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent111424">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/23/12/36416440/why-buy-stocks-in-a-presidential-election-year-history-has-a-crazy-stat-for-you">Benzinga previously reported</a> that presidential election years are often good for investors with 14 of the last 16, not including 2024, seeing the S&amp;P 500 Index trade higher. The only two presidential election years of the last 16 to not have a positive return were the global financial crisis (2008) and the dot-com bubble (2000).
The SPDR S&amp;P 500 ETF Trust is currently up 26.4% year-to-date in 2024. While that amount could go up or down, the return is currently among the highest in recent presidential election years.
If the 26.4% gain holds or comes in higher, 2024 would mark the best-performing presidential election year for the S&amp;P 500 since 1980 (+32.4%), beating the current record holder, 1996, which saw the index up 23.1%.
The 2024 return of the S&amp;P 500 could also come as one of the best in recent years. Here are the recent returns of the S&amp;P 500 ETF Trust:
<ul>
<li>2023: +26.2%</li>
<li>2022: -18.2%</li>
<li>2021: +28.8%</li>
<li>2020: +18.4%</li>
<li>2019: +31.2%</li>
<li>2018: -4.6%</li>
<li>2017: +21.7%</li>
<li>2016: +12.0%</li>
</ul>
With the ETF up 26.4% year-to-date, the SPY is currently ahead of the 2023 return, but down from the returns posted in 2021 and 2019.
If the stock market continues to trade higher and hits record highs, there's a chance that the SPY passes those figures and could be the best performing year for the ETF in over 10 years, with 2013 being up 32.3%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/10/41584466/these-10-stocks-were-the-best-s-p-500-performers-in-2017-when-trump-was-president-will-history-r">These 10 Stocks Were The Best S&amp;P 500 Performers In 2017 When Trump Was President: Will History Repeat Itself?</a></li>
</ul>
The study was conducted by Benzinga from Nov. 6 through Nov. 7, 2024, and included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 146 adults.
Photo: Shutterstock

Politics

Will Trump's Election Win Push S&P 500 Even Higher In Final Weeks Of 2024? Over 75% Say...

Ford Motor's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) short percent of float has risen 6.5% since its last report. The company recently reported that it has 106.07 million shares sold short, which is 2.95% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.82 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ford Motor Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731598224_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ford Motor has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Ford Motor's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ford Motor's peer group average for short interest as a percentage of float is 7.88%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Ford Motor's Recent Short Interest

argenx's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NYSE">ARGX</a>) short percent of float has fallen 4.38% since its last report. The company recently reported that it has 1.70 million shares sold short, which is 2.84% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.12 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>argenx Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731598218_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for argenx has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing argenx's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, argenx's peer group average for short interest as a percentage of float is 5.09%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ARGX

(ARGX) - Analyzing argenx's Short Interest

Air Products &amp; Chemicals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) short percent of float has fallen 19.19% since its last report. The company recently reported that it has 3.54 million shares sold short, which is 1.6% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.61 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Air Products &amp; Chemicals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731598213_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Air Products &amp; Chemicals has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Air Products &amp; Chemicals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Air Products &amp; Chemicals's peer group average for short interest as a percentage of float is 3.12%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Air Products & Chemicals's Recent Short Interest

ASP Isotopes Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>) shares are trading higher. The company on Thursday announced a deal to collaborate on an advanced <a href="https://www.benzinga.com/pressreleases/24/11/g41970030/asp-isotopes-inc-enters-into-memorandum-of-understanding-with-the-south-african-nuclear-energy-cor">nuclear fuel production facility</a>.
What Happened: ASP Isotopes entered into a Memorandum of Understanding (MOU) with The South African Nuclear Energy Corporation (Necsa) to collaborate on the research, development and commercial production of advanced nuclear fuels.
The MOU contemplates the formation of a new entity in South Africa with a board consisting of at least two representatives from ASP Isotopes and Necsa. The company said discussions between the parties in recent years have centered on advancing new nuclear fuel for small modular reactors at the start, and eventually working toward a nuclear fuel facility for the production of High Assay Low-Enriched Uranium (HALEU).
&#8220;Nuclear fuel has one of the most severely compromised supply chains&nbsp;of any material in the World. The World is in urgent need of additional suppliers.&nbsp;This partnership with Necsa will enable us to accelerate the construction of an advanced nuclear fuel facility,&#8221; said Paul Mann, chairman and CEO of ASP Isotopes.
Check This Out: <a href="https://www.benzinga.com/top-stories/24/11/41915547/trumps-fossil-fuel-push-may-satisfy-ais-soaring-energy-demand-but-what-about-nuclear">Trump&#8217;s Fossil Fuel Push May Satisfy AI&#8217;s Soaring Energy Demand — But What About Nuclear?</a>
ASP Isotopes shares are up more than 100% over the past month as several nuclear names have benefitted from an increased focus from hyperscalers aiming to keep up with rising energy demand related to AI data centers. 
ASP Isotopes shares surged at the end of October after the company signed a deal with Bill Gates-backed <a href="https://www.benzinga.com/news/24/10/41624818/asp-isotopes-stock-is-soaring-wednesday-whats-going-on">TerraPower</a> related to&nbsp;the construction of a uranium enrichment facility capable of producing HALEU.
ASP on Thursday said it has received interest from potential customers who collectively require over $37 billion of HALEU between now and 2037.
ASPI Price Action: <a href="http://benzinga.com/quote/aspi" target="_blank" rel="noreferrer noopener">ASP Isotopes shares</a> were up 5.32% at $7.88 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Shutterstock.

Contracts

ASPI

ASP Isotopes Stock Is Moving Higher Thursday: What's Going On?

RBC Capital analyst Sabahat Khan maintains Finning International (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FTT#TSX">FTT</a>) with a Outperform and lowers the price target from C$50 to C$46.

TSX:FTT

RBC Capital Maintains Outperform on Finning International, Lowers Price Target to C$46

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Reviva Pharmaceuticals Holdings (RVPH – Research Report), retaining the price t...

Buy Rating Reaffirmed for Reviva Pharmaceuticals: Patent Protection and Promising Drug Pipeline Fuel Positive Outlook

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Reviva Pharmaceuticals Holdings (RVPH – Research Report) and keeping the pric...

Buy Rating Affirmed for Reviva Pharmaceuticals Amid Patent Grants and Positive Clinical Outlook

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Reviva Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/rvph-stock-quote/">RVPH</a>) just reported results for the second quarter of 2024.<ul><li>Reviva Pharmaceuticals reported earnings per share of -26 cents. This was above the analyst estimate for EPS of -29 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/rvph-stock-earnings-reviva-pharmaceuticals-for-q2-of-2024/">RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q2 2024

Reviva Pharmaceuticals GAAP EPS of -$0.26

Reviva Pharmaceuticals stock falls after it prices $5M offering

The latest update is out from Reviva Pharmaceuticals Holdings (RVPH). Reviva Pharmaceuticals Holdings, Inc. has embarked on a financial maneuver wi...

Reviva Pharmaceuticals Launches Multi-Million Share Offering

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on Reviva Pharmaceuticals Holdings (RVPH – Research Report...

Maxim Group Reaffirms Their Hold Rating on Reviva Pharmaceuticals Holdings (RVPH)

Reviva Pharmaceuticals (RVPH) announced an enrollment update to the ongoing 1-year open-label extension, OLE, study evaluating the long-term safety...

Reviva announces enrollment update for OLE study of brilaroxazine

An announcement from Reviva Pharmaceuticals Holdings ( ($RVPH) ) is now available. Reviva Pharmaceuticals announced an enrollment update for its op...

Reviva Pharmaceuticals Progresses with Brilaroxazine Study Update

Maxim Group analyst Jason McCarthy maintained a Hold rating on Reviva Pharmaceuticals Holdings (RVPH – Research Report) yesterday. The company's sh...

Comments

Reviva Pharmaceuticals

Noticias

Últimas noticias sobre Reviva Pharmaceuticals (NASDAQ:RVPH) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL